InspireMD

About

Funding history · 11 rounds · $248.8M total

Headcount over time

Offices

Q&A

What is InspireMD's primary focus as a medical technology company?

InspireMD is a medical technology company focused on innovative solutions for the treatment of vascular disease, advancing embolic protection to improve patient outcomes. They utilize their proprietary MicroNet® mesh platform technology to develop products for the prevention of stroke and treatment of complex vascular and coronary disease.

When did InspireMD announce the FDA approval for its CGuard® Prime Carotid Stent System?

InspireMD announced FDA approval for its CGuard® Prime Carotid Stent System for the prevention of stroke on June 24, 2025.

What was the most recent funding event for InspireMD and its amount?

InspireMD completed a Public Offering in April 2026, raising $75,000,000.

What was the total amount of capital raised by InspireMD through all its funding rounds?

InspireMD has raised a total of $229,480,000 across all its funding rounds.

What was a significant operational development for InspireMD in October 2024?

In October 2024, InspireMD announced the establishment of its Global Headquarters in Miami, Florida, to support the anticipated U.S. launch and commercialization of the CGuard Prime Carotid Stent System.

What was a key regulatory achievement for InspireMD in January 2024?

In January 2024, InspireMD received CE Mark Recertification under the EU’s new Medical Device Regulation (MDR) Regulatory Framework.

What was the purpose of the partnership between InspireMD and NAMSA announced in February 2025?

In February 2025, InspireMD and NAMSA partnered on the CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for use in TCAR procedures.

What was a notable leadership change announced by InspireMD in June 2025?

In June 2025, InspireMD announced the appointment of Michael Lawless as Chief Financial Officer.

What was the outcome of the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial announced in June 2023?

In June 2023, InspireMD announced the completion of enrollment in the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial.

What is the current employee count for InspireMD?

InspireMD has 51-200 employees.

Team · 13

Marvin Slosman

CEO

Michael Lawless

CFO

Amir Kohen

EVP Finance & Regional Manager

Kathleen Kennedy

Senior Vice President of Global Sales and Marketing

Vince Turturro

Sr. Vice President of Research & Development

Sonali Dewan

Vice President of Regulatory & Clinical Affairs and Quality Assurance

Donna DeChant

Vice President Human Resources & Organizational Development

Peter Soukas, MD

Chief Medical Officer

Paul Stuka

Chairman of the Board of Directors

Michael Berman

Independent Director

Gary Roubin, M.D., Ph.D

Board of Directors

Scott R. Ward

Board of Directors

Dan Dearen

Independent Director

Sectors & technology

Highlights

Tags